#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-9	Doxazosin	_
1-2	10-13	for	_
1-3	14-17	the	_
1-4	18-27	treatment	_
1-5	28-30	of	_
1-6	31-43	co-occurring	_
1-7	44-48	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
1-8	49-52	and	_
1-9	53-60	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
1-10	61-64	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
1-11	65-73	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
1-12	74-75	:	_
1-13	76-82	Design	_
1-14	83-86	and	_
1-15	87-98	methodology	_
1-16	99-101	of	_
1-17	102-103	a	_
1-18	104-114	randomized	_
1-19	115-125	controlled	_
1-20	126-131	trial	_
1-21	132-134	in	_
1-22	135-143	military	_
1-23	144-152	veterans	_
1-24	153-166	Posttraumatic	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
1-25	167-173	stress	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
1-26	174-182	disorder	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
1-27	183-184	(	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
1-28	185-189	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
1-29	190-191	)	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
1-30	192-195	and	_
1-31	196-203	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
1-32	204-207	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
1-33	208-217	disorders	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
1-34	218-219	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
1-35	220-223	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
1-36	224-225	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
1-37	226-229	are	_
1-38	230-233	two	_
1-39	234-236	of	_
1-40	237-240	the	_
1-41	241-245	most	_
1-42	246-252	common	_
1-43	253-259	mental	_
1-44	260-266	health	_
1-45	267-276	disorders	_
1-46	277-286	affecting	_
1-47	287-296	civilians	_
1-48	297-299	as	_
1-49	300-304	well	_
1-50	305-307	as	_
1-51	308-316	military	_
1-52	317-328	populations	_
1-53	329-330	.	_

2-1	331-333	If	_
2-2	334-338	left	_
2-3	339-348	untreated	_
2-4	349-350	,	_
2-5	351-362	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
2-6	363-367	with	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
2-7	368-380	co-occurring	_
2-8	381-389	PTSD/AUD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
2-9	390-393	are	_
2-10	394-396	at	_
2-11	397-406	increased	_
2-12	407-411	risk	_
2-13	412-415	for	_
2-14	416-426	developing	_
2-15	427-432	other	_
2-16	433-439	mental	_
2-17	440-446	health	_
2-18	447-455	problems	_
2-19	456-457	(	_
2-20	458-462	e.g.	_
2-21	463-464	,	_
2-22	465-475	depression	_
2-23	476-477	,	_
2-24	478-485	anxiety	_
2-25	486-487	)	_
2-26	488-489	,	_
2-27	490-498	physical	_
2-28	499-505	health	_
2-29	506-514	problems	_
2-30	515-516	,	_
2-31	517-524	reduced	_
2-32	525-535	resiliency	_
2-33	536-539	and	_
2-34	540-548	military	_
2-35	549-558	readiness	_
2-36	559-560	,	_
2-37	561-564	and	_
2-38	565-575	vocational	_
2-39	576-579	and	_
2-40	580-586	social	_
2-41	587-597	impairment	_
2-42	598-599	.	_

3-1	600-611	Substantial	_
3-2	612-616	gaps	_
3-3	617-619	in	_
3-4	620-623	the	_
3-5	624-633	treatment	_
3-6	634-636	of	_
3-7	637-649	co-occurring	_
3-8	650-658	PTSD/AUD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
3-9	659-664	exist	_
3-10	665-668	and	_
3-11	669-674	there	_
3-12	675-677	is	_
3-13	678-679	a	_
3-14	680-688	critical	_
3-15	689-693	need	_
3-16	694-696	to	_
3-17	697-704	develop	_
3-18	705-709	more	_
3-19	710-719	effective	_
3-20	720-735	pharmacological	_
3-21	736-746	treatments	_
3-22	747-748	.	_

4-1	749-752	The	_
4-2	753-760	current	_
4-3	761-766	study	_
4-4	767-776	addresses	_
4-5	777-781	this	_
4-6	782-785	gap	_
4-7	786-788	in	_
4-8	789-792	the	_
4-9	793-803	literature	_
4-10	804-806	by	_
4-11	807-814	testing	_
4-12	815-818	the	_
4-13	819-827	efficacy	_
4-14	828-831	and	_
4-15	832-838	safety	_
4-16	839-841	of	_
4-17	842-851	doxazosin	_
4-18	852-853	,	_
4-19	854-855	a	_
4-20	856-867	long-acting	_
4-21	868-871	and	_
4-22	872-881	selective	_
4-23	882-889	alpha-1	_
4-24	890-900	adrenergic	_
4-25	901-911	antagonist	_
4-26	912-913	,	_
4-27	914-916	as	_
4-28	917-925	compared	_
4-29	926-928	to	_
4-30	929-936	placebo	_
4-31	937-939	in	_
4-32	940-948	reducing	_
4-33	949-953	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
4-34	954-957	and	_
4-35	958-961	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
4-36	962-970	severity	_
4-37	971-976	among	_
4-38	977-981	U.S.	_
4-39	982-990	military	_
4-40	991-999	veterans	_
4-41	1000-1001	.	_

5-1	1002-1015	Noradrenergic	_
5-2	1016-1029	dysregulation	_
5-3	1030-1033	has	_
5-4	1034-1038	been	_
5-5	1039-1049	implicated	_
5-6	1050-1052	in	_
5-7	1053-1056	the	_
5-8	1057-1068	development	_
5-9	1069-1072	and	_
5-10	1073-1084	maintenance	_
5-11	1085-1087	of	_
5-12	1088-1092	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
5-13	1093-1096	and	_
5-14	1097-1100	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
5-15	1101-1102	,	_
5-16	1103-1106	and	_
5-17	1107-1112	pilot	_
5-18	1113-1120	studies	_
5-19	1121-1130	examining	_
5-20	1131-1140	doxazosin	_
5-21	1141-1143	in	_
5-22	1144-1153	PTSD-only	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
5-23	1154-1156	or	_
5-24	1157-1165	AUD-only	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
5-25	1166-1173	samples	_
5-26	1174-1178	have	_
5-27	1179-1184	shown	_
5-28	1185-1192	promise	_
5-29	1193-1194	.	_

6-1	1195-1199	This	_
6-2	1200-1202	is	_
6-3	1203-1206	the	_
6-4	1207-1212	first	_
6-5	1213-1218	study	_
6-6	1219-1220	,	_
6-7	1221-1228	however	_
6-8	1229-1230	,	_
6-9	1231-1233	to	_
6-10	1234-1242	evaluate	_
6-11	1243-1252	doxazosin	_
6-12	1253-1255	in	_
6-13	1256-1257	a	_
6-14	1258-1266	comorbid	_
6-15	1267-1275	PTSD/AUD	_
6-16	1276-1282	sample	_
6-17	1283-1284	.	_

7-1	1285-1289	This	_
7-2	1290-1295	paper	_
7-3	1296-1305	describes	_
7-4	1306-1309	the	_
7-5	1310-1319	rationale	_
7-6	1320-1321	,	_
7-7	1322-1328	design	_
7-8	1329-1332	and	_
7-9	1333-1344	methodology	_
7-10	1345-1347	of	_
7-11	1348-1349	a	_
7-12	1350-1360	randomized	_
7-13	1361-1362	,	_
7-14	1363-1375	double-blind	_
7-15	1376-1377	,	_
7-16	1378-1396	placebo-controlled	_
7-17	1397-1402	trial	_
7-18	1403-1405	of	_
7-19	1406-1415	doxazosin	_
7-20	1416-1417	(	_
7-21	1418-1420	16	_
7-22	1421-1427	mg/day	_
7-23	1428-1429	)	_
7-24	1430-1439	delivered	_
7-25	1440-1444	over	_
7-26	1445-1447	12	_
7-27	1448-1453	weeks	_
7-28	1454-1459	among	_
7-29	1460-1468	military	_
7-30	1469-1477	veterans	_
7-31	1478-1482	with	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
7-32	1483-1490	current	_
7-33	1491-1495	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
7-34	1496-1499	and	_
7-35	1500-1503	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
7-36	1504-1505	.	_

8-1	1506-1508	In	_
8-2	1509-1517	addition	_
8-3	1518-1519	,	_
8-4	1520-1530	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-5	1531-1539	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-6	1540-1549	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-7	1550-1557	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-8	1558-1559	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-9	1560-1564	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-10	1565-1566	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-11	1567-1569	is	_
8-12	1570-1577	applied	_
8-13	1578-1580	at	_
8-14	1581-1585	pre-	_
8-15	1586-1589	and	_
8-16	1590-1604	post-treatment	_
8-17	1605-1607	to	_
8-18	1608-1619	investigate	_
8-19	1620-1623	the	_
8-20	1624-1634	underlying	_
8-21	1635-1650	pathophysiology	_
8-22	1651-1653	of	_
8-23	1654-1662	comorbid	_
8-24	1663-1671	PTSD/AUD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
8-25	1672-1675	and	_
8-26	1676-1684	identify	_
8-27	1685-1695	prognostic	_
8-28	1696-1706	indicators	_
8-29	1707-1709	of	_
8-30	1710-1719	treatment	_
8-31	1720-1727	outcome	_
8-32	1728-1729	.	_

9-1	1730-1734	This	_
9-2	1735-1740	study	_
9-3	1741-1743	is	_
9-4	1744-1752	designed	_
9-5	1753-1755	to	_
9-6	1756-1766	accelerate	_
9-7	1767-1775	research	_
9-8	1776-1778	on	_
9-9	1779-1791	co-occurring	_
9-10	1792-1800	PTSD/AUD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
9-11	1801-1804	and	_
9-12	1805-1812	provide	_
9-13	1813-1822	empirical	_
9-14	1823-1831	evidence	_
9-15	1832-1834	to	_
9-16	1835-1841	inform	_
9-17	1842-1850	clinical	_
9-18	1851-1859	practice	_
9-19	1860-1861	.	_

10-1	1862-1871	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-2	1872-1875	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	1876-1883	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	1884-1892	Research	_
10-5	1893-1899	design	_
10-6	1900-1904	This	_
10-7	1905-1910	study	_
10-8	1911-1913	is	_
10-9	1914-1915	a	_
10-10	1916-1921	phase	_
10-11	1922-1924	II	_
10-12	1925-1926	,	_
10-13	1927-1939	double-blind	_
10-14	1940-1941	,	_
10-15	1942-1949	12-week	_
10-16	1950-1953	RCT	_
10-17	1954-1956	to	_
10-18	1957-1965	evaluate	_
10-19	1966-1969	the	_
10-20	1970-1978	efficacy	_
10-21	1979-1981	of	_
10-22	1982-1985	the	_
10-23	1986-1993	alpha-1	_
10-24	1994-2004	adrenergic	_
10-25	2005-2015	antagonist	_
10-26	2016-2025	doxazosin	_
10-27	2026-2027	(	_
10-28	2028-2030	16	_
10-29	2031-2037	mg/day	_
10-30	2038-2039	,	_
10-31	2040-2049	immediate	_
10-32	2050-2057	release	_
10-33	2058-2069	formulation	_
10-34	2070-2071	)	_
10-35	2072-2073	,	_
10-36	2074-2076	as	_
10-37	2077-2085	compared	_
10-38	2086-2088	to	_
10-39	2089-2096	placebo	_
10-40	2097-2099	in	_
10-41	2100-2108	reducing	_
10-42	2109-2113	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
10-43	2114-2117	and	_
10-44	2118-2121	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
10-45	2122-2130	severity	_
10-46	2131-2133	in	_
10-47	2134-2142	veterans	_
10-48	2143-2144	.	_

11-1	2145-2146	A	_
11-2	2147-2156	follow-up	_
11-3	2157-2162	visit	_
11-4	2163-2165	is	_
11-5	2166-2174	included	_
11-6	2175-2177	at	_
11-7	2178-2185	6-weeks	_
11-8	2186-2190	post	_
11-9	2191-2200	treatment	_
11-10	2201-2202	.	_

12-1	2203-2205	If	_
12-2	2206-2214	eligible	_
12-3	2215-2218	and	_
12-4	2219-2229	interested	_
12-5	2230-2231	,	_
12-6	2232-2244	participants	_
12-7	2245-2248	may	_
12-8	2249-2253	also	_
12-9	2254-2262	complete	_
12-10	2263-2264	a	_
12-11	2265-2277	neuroimaging	_
12-12	2278-2282	scan	_
12-13	2283-2289	before	_
12-14	2290-2293	and	_
12-15	2294-2299	after	_
12-16	2300-2303	the	_
12-17	2304-2313	treatment	_
12-18	2314-2319	phase	_
12-19	2320-2321	.	_

13-1	2322-2325	The	_
13-2	2326-2333	project	_
13-3	2334-2338	will	_
13-4	2339-2343	last	_
13-5	2344-2347	for	_
13-6	2348-2361	approximately	_
13-7	2362-2366	four	_
13-8	2367-2372	years	_
13-9	2373-2376	and	_
13-10	2377-2379	is	_
13-11	2380-2391	illustrated	_
13-12	2392-2394	in	_
13-13	2395-2398	Fig	_
13-14	2399-2400	.	_

14-1	2401-2402	1	_
14-2	2403-2404	(	_
14-3	2405-2413	clinical	_
14-4	2414-2419	trial	_
14-5	2420-2421	)	_
14-6	2422-2425	and	_
14-7	2426-2429	Fig	_
14-8	2430-2431	.	_

15-1	2432-2433	2	_
15-2	2434-2435	(	_
15-3	2436-2448	neuroimaging	_
15-4	2449-2454	visit	_
15-5	2455-2456	)	_
15-6	2457-2458	.	_

16-1	2459-2471	Participants	_
16-2	2472-2484	Participants	_
16-3	2485-2486	(	_
16-4	2487-2488	N	_
16-5	2489-2490	=	_
16-6	2491-2494	144	_
16-7	2495-2496	)	_
16-8	2497-2500	are	_
16-9	2501-2505	U.S.	_
16-10	2506-2514	military	_
16-11	2515-2523	veterans	_
16-12	2524-2525	,	_
16-13	2526-2530	ages	_
16-14	2531-2536	18–65	_
16-15	2537-2538	,	_
16-16	2539-2543	with	_
16-17	2544-2551	current	_
16-18	2552-2556	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
16-19	2557-2560	and	_
16-20	2561-2564	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
16-21	2565-2566	.	_

17-1	2567-2576	Inclusion	_
17-2	2577-2585	criteria	_
17-3	2586-2593	include	_
17-4	2594-2595	:	_
17-5	2596-2597	a	_
17-6	2598-2605	veteran	_
17-7	2606-2608	of	_
17-8	2609-2612	the	_
17-9	2613-2617	U.S.	_
17-10	2618-2626	military	_
17-11	2627-2628	(	_
17-12	2629-2632	any	_
17-13	2633-2639	branch	_
17-14	2640-2641	)	_
17-15	2642-2643	,	_
17-16	2644-2648	male	_
17-17	2649-2651	or	_
17-18	2652-2658	female	_
17-19	2659-2660	,	_
17-20	2661-2664	any	_
17-21	2665-2669	race	_
17-22	2670-2672	or	_
17-23	2673-2682	ethnicity	_
17-24	2683-2684	,	_
17-25	2685-2689	able	_
17-26	2690-2692	to	_
17-27	2693-2703	comprehend	_
17-28	2704-2711	English	_
17-29	2712-2713	,	_
17-30	2714-2718	meet	_
17-31	2719-2724	DSM-5	_
17-32	2725-2733	criteria	_
17-33	2734-2737	for	_
17-34	2738-2745	current	_
17-35	2746-2747	(	_
17-36	2748-2752	i.e.	_
17-37	2753-2754	,	_
17-38	2755-2759	last	_
17-39	2760-2761	6	_
17-40	2762-2768	months	_
17-41	2769-2770	)	_
17-42	2771-2778	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
17-43	2779-2782	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
17-44	2783-2791	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
17-45	2792-2794	as	_
17-46	2795-2803	assessed	_
17-47	2804-2806	by	_
17-48	2807-2810	the	_
17-49	2811-2815	Mini	_
17-50	2816-2829	International	_
17-51	2830-2846	Neuropsychiatric	_
17-52	2847-2856	Interview	_
17-53	2857-2858	(	_
17-54	2859-2863	MINI	_
17-55	2864-2865	,	_
17-56	2866-2870	meet	_
17-57	2871-2876	DSM-5	_
17-58	2877-2885	criteria	_
17-59	2886-2889	for	_
17-60	2890-2897	current	_
17-61	2898-2899	(	_
17-62	2900-2904	i.e.	_
17-63	2905-2906	,	_
17-64	2907-2911	last	_
17-65	2912-2917	month	_
17-66	2918-2919	)	_
17-67	2920-2924	PTSD	_
17-68	2925-2927	as	_
17-69	2928-2936	assessed	_
17-70	2937-2939	by	_
17-71	2940-2943	the	_
17-72	2944-2950	CAPS-5	_
17-73	2951-2952	(	_
17-74	2953-2961	Weathers	_
17-75	2962-2964	et	_
17-76	2965-2968	al.	_
17-77	2969-2970	,	_
17-78	2971-2975	2013	_
17-79	2976-2977	)	_
17-80	2978-2979	,	_
17-81	2980-2983	and	_
17-82	2984-2992	enrolled	_
17-83	2993-2996	for	_
17-84	2997-3005	services	_
17-85	3006-3008	at	_
17-86	3009-3012	the	_
17-87	3013-3018	Ralph	_
17-88	3019-3021	H.	_
17-89	3022-3029	Johnson	_
17-90	3030-3032	VA	_
17-91	3033-3040	Medical	_
17-92	3041-3047	Center	_
17-93	3048-3050	or	_
17-94	3051-3061	affiliated	_
17-95	3062-3077	community-based	_
17-96	3078-3088	outpatient	_
17-97	3089-3095	clinic	_
17-98	3096-3097	.	_

18-1	3098-3106	Subjects	_
18-2	3107-3113	taking	_
18-3	3114-3126	psychotropic	_
18-4	3127-3138	medications	_
18-5	3139-3142	are	_
18-6	3143-3151	required	_
18-7	3152-3154	to	_
18-8	3155-3157	be	_
18-9	3158-3168	maintained	_
18-10	3169-3171	on	_
18-11	3172-3173	a	_
18-12	3174-3180	stable	_
18-13	3181-3185	dose	_
18-14	3186-3189	for	_
18-15	3190-3192	at	_
18-16	3193-3198	least	_
18-17	3199-3200	4	_
18-18	3201-3206	weeks	_
18-19	3207-3213	before	_
18-20	3214-3219	study	_
18-21	3220-3230	medication	_
18-22	3231-3241	initiation	_
18-23	3242-3243	.	_

19-1	3244-3253	Exclusion	_
19-2	3254-3262	criteria	_
19-3	3263-3270	include	_
19-4	3271-3274	the	_
19-5	3275-3284	following	_
19-6	3285-3286	:	_
19-7	3287-3295	previous	_
19-8	3296-3305	treatment	_
19-9	3306-3310	with	_
19-10	3311-3320	doxazosin	_
19-11	3321-3322	;	_
19-12	3323-3328	women	_
19-13	3329-3332	who	_
19-14	3333-3336	are	_
19-15	3337-3345	pregnant	_
19-16	3346-3347	,	_
19-17	3348-3355	nursing	_
19-18	3356-3358	or	_
19-19	3359-3362	not	_
19-20	3363-3373	practicing	_
19-21	3374-3376	an	_
19-22	3377-3386	effective	_
19-23	3387-3391	form	_
19-24	3392-3394	of	_
19-25	3395-3400	birth	_
19-26	3401-3408	control	_
19-27	3409-3410	;	_
19-28	3411-3422	individuals	_
19-29	3423-3427	with	_
19-30	3428-3429	a	_
19-31	3430-3437	history	_
19-32	3438-3440	of	_
19-33	3441-3448	adverse	_
19-34	3449-3458	reactions	_
19-35	3459-3461	to	_
19-36	3462-3474	quinazolines	_
19-37	3475-3477	or	_
19-38	3478-3483	other	_
19-39	3484-3503	alpha-1-antagonists	_
19-40	3504-3505	;	_
19-41	3506-3517	individuals	_
19-42	3518-3527	currently	_
19-43	3528-3534	taking	_
19-44	3535-3540	alpha	_
19-45	3541-3549	blockers	_
19-46	3550-3551	(	_
19-47	3552-3556	e.g.	_
19-48	3557-3558	,	_
19-49	3559-3567	prazosin	_
19-50	3568-3569	)	_
19-51	3570-3572	or	_
19-52	3573-3576	any	_
19-53	3577-3582	other	_
19-54	3583-3593	medication	_
19-55	3594-3598	that	_
19-56	3599-3602	may	_
19-57	3603-3607	have	_
19-58	3608-3609	a	_
19-59	3610-3619	hazardous	_
19-60	3620-3631	interaction	_
19-61	3632-3634	if	_
19-62	3635-3640	taken	_
19-63	3641-3645	with	_
19-64	3646-3655	doxazosin	_
19-65	3656-3657	;	_
19-66	3658-3661	and	_
19-67	3662-3673	individuals	_
19-68	3674-3678	with	_
19-69	3679-3689	clinically	_
19-70	3690-3701	significant	_
19-71	3702-3709	medical	_
19-72	3710-3712	or	_
19-73	3713-3724	psychiatric	_
19-74	3725-3735	conditions	_
19-75	3736-3740	that	_
19-76	3741-3743	in	_
19-77	3744-3747	the	_
19-78	3748-3755	opinion	_
19-79	3756-3758	of	_
19-80	3759-3762	the	_
19-81	3763-3776	investigators	_
19-82	3777-3780	may	_
19-83	3781-3790	adversely	_
19-84	3791-3797	affect	_
19-85	3798-3804	safety	_
19-86	3805-3807	or	_
19-87	3808-3813	study	_
19-88	3814-3827	participation	_
19-89	3828-3829	.	_

20-1	3830-3841	Individuals	_
20-2	3842-3852	presenting	_
20-3	3853-3857	with	_
20-4	3858-3869	significant	_
20-5	3870-3880	withdrawal	_
20-6	3881-3889	symptoms	_
20-7	3890-3892	as	_
20-8	3893-3902	evidenced	_
20-9	3903-3905	by	_
20-10	3906-3907	a	_
20-11	3908-3913	score	_
20-12	3914-3916	on	_
20-13	3917-3920	the	_
20-14	3921-3928	revised	_
20-15	3929-3938	Clinician	_
20-16	3939-3948	Institute	_
20-17	3949-3959	Withdrawal	_
20-18	3960-3970	Assessment	_
20-19	3971-3973	of	_
20-20	3974-3981	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
20-21	3982-3983	(	_
20-22	3984-3991	CIWA-Ar	_
20-23	3992-3993	)	_
20-24	3994-3996	of	_
20-25	3997-4000	≥10	_
20-26	4001-4005	will	_
20-27	4006-4008	be	_
20-28	4009-4017	referred	_
20-29	4018-4021	for	_
20-30	4022-4031	medically	_
20-31	4032-4042	supervised	_
20-32	4043-4057	detoxification	_
20-33	4058-4061	and	_
20-34	4062-4065	may	_
20-35	4066-4068	be	_
20-36	4069-4080	re-assessed	_
20-37	4081-4084	for	_
20-38	4085-4090	study	_
20-39	4091-4102	eligibility	_
20-40	4103-4108	after	_
20-41	4109-4123	detoxification	_
20-42	4124-4125	.	_

21-1	4126-4137	Individuals	_
21-2	4138-4144	taking	_
21-3	4145-4156	medications	_
21-4	4157-4164	thought	_
21-5	4165-4167	to	_
21-6	4168-4177	influence	_
21-7	4178-4185	alcohol	_
21-8	4186-4197	consumption	_
21-9	4198-4200	or	_
21-10	4201-4208	craving	_
21-11	4209-4210	(	_
21-12	4211-4215	e.g.	_
21-13	4216-4217	,	_
21-14	4218-4228	naltrexone	_
21-15	4229-4230	)	_
21-16	4231-4235	will	_
21-17	4236-4238	be	_
21-18	4239-4247	excluded	_
21-19	4248-4249	.	_

22-1	4250-4253	MRI	_
22-2	4254-4264	exclusions	_
22-3	4265-4272	include	_
22-4	4273-4287	claustrophobia	_
22-5	4288-4289	;	_
22-6	4290-4297	cardiac	_
22-7	4298-4307	pacemaker	_
22-8	4308-4309	;	_
22-9	4310-4315	metal	_
22-10	4316-4325	fragments	_
22-11	4326-4328	in	_
22-12	4329-4332	eye	_
22-13	4333-4334	,	_
22-14	4335-4339	skin	_
22-15	4340-4341	,	_
22-16	4342-4344	or	_
22-17	4345-4349	body	_
22-18	4350-4351	;	_
22-19	4352-4357	heart	_
22-20	4358-4363	valve	_
22-21	4364-4375	replacement	_
22-22	4376-4377	;	_
22-23	4378-4383	brain	_
22-24	4384-4389	clips	_
22-25	4390-4391	;	_
22-26	4392-4398	venous	_
22-27	4399-4407	umbrella	_
22-28	4408-4409	;	_
22-29	4410-4417	history	_
22-30	4418-4420	of	_
22-31	4421-4429	aneurysm	_
22-32	4430-4437	surgery	_
22-33	4438-4439	;	_
22-34	4440-4452	intracranial	_
22-35	4453-4459	bypass	_
22-36	4460-4461	,	_
22-37	4462-4467	renal	_
22-38	4468-4469	,	_
22-39	4470-4472	or	_
22-40	4473-4479	aortic	_
22-41	4480-4485	clips	_
22-42	4486-4487	;	_
22-43	4488-4493	joint	_
22-44	4494-4506	replacements	_
22-45	4507-4508	;	_
22-46	4509-4522	non-removable	_
22-47	4523-4530	hearing	_
22-48	4531-4534	aid	_
22-49	4535-4536	,	_
22-50	4537-4552	neurostimulator	_
22-51	4553-4555	or	_
22-52	4556-4563	insulin	_
22-53	4564-4568	pump	_
22-54	4569-4570	;	_
22-55	4571-4584	shunts/stents	_
22-56	4585-4586	;	_
22-57	4587-4592	metal	_
22-58	4593-4602	mesh/coil	_
22-59	4603-4611	implants	_
22-60	4612-4613	;	_
22-61	4614-4619	metal	_
22-62	4620-4642	plate/pin/screws/wires	_
22-63	4643-4644	;	_
22-64	4645-4647	or	_
22-65	4648-4651	any	_
22-66	4652-4657	other	_
22-67	4658-4663	metal	_
22-68	4664-4672	implants	_
22-69	4673-4674	.	_

23-1	4675-4685	Procedures	_
23-2	4686-4690	This	_
23-3	4691-4696	study	_
23-4	4697-4700	was	_
23-5	4701-4709	reviewed	_
23-6	4710-4713	and	_
23-7	4714-4722	approved	_
23-8	4723-4725	by	_
23-9	4726-4729	the	_
23-10	4730-4743	Institutional	_
23-11	4744-4750	Review	_
23-12	4751-4757	Boards	_
23-13	4758-4759	(	_
23-14	4760-4763	IRB	_
23-15	4764-4765	)	_
23-16	4766-4768	of	_
23-17	4769-4772	the	_
23-18	4773-4780	Medical	_
23-19	4781-4791	University	_
23-20	4792-4794	of	_
23-21	4795-4800	South	_
23-22	4801-4809	Carolina	_
23-23	4810-4811	(	_
23-24	4812-4816	MUSC	_
23-25	4817-4818	)	_
23-26	4819-4820	,	_
23-27	4821-4824	the	_
23-28	4825-4830	Ralph	_
23-29	4831-4833	H.	_
23-30	4834-4841	Johnson	_
23-31	4842-4844	VA	_
23-32	4845-4852	Medical	_
23-33	4853-4859	Center	_
23-34	4860-4861	,	_
23-35	4862-4865	and	_
23-36	4866-4869	the	_
23-37	4870-4880	University	_
23-38	4881-4883	of	_
23-39	4884-4889	Texas	_
23-40	4890-4896	Health	_
23-41	4897-4904	Science	_
23-42	4905-4911	Center	_
23-43	4912-4914	at	_
23-44	4915-4918	San	_
23-45	4919-4926	Antonio	_
23-46	4927-4928	.	_

24-1	4929-4938	Potential	_
24-2	4939-4951	participants	_
24-3	4952-4955	are	_
24-4	4956-4961	given	_
24-5	4962-4963	a	_
24-6	4964-4968	full	_
24-7	4969-4980	description	_
24-8	4981-4983	of	_
24-9	4984-4987	the	_
24-10	4988-4993	study	_
24-11	4994-4997	and	_
24-12	4998-5003	asked	_
24-13	5004-5006	to	_
24-14	5007-5011	read	_
24-15	5012-5015	and	_
24-16	5016-5020	sign	_
24-17	5021-5033	IRB-approved	_
24-18	5034-5042	informed	_
24-19	5043-5050	consent	_
24-20	5051-5056	forms	_
24-21	5057-5063	before	_
24-22	5064-5067	any	_
24-23	5068-5073	study	_
24-24	5074-5084	procedures	_
24-25	5085-5089	take	_
24-26	5090-5095	place	_
24-27	5096-5097	.	_

25-1	5098-5101	All	_
25-2	5102-5114	participants	_
25-3	5115-5118	are	_
25-4	5119-5127	enrolled	_
25-5	5128-5130	in	_
25-6	5131-5134	the	_
25-7	5135-5137	VA	_
25-8	5138-5141	and	_
25-9	5142-5146	have	_
25-10	5147-5150	the	_
25-11	5151-5157	option	_
25-12	5158-5160	to	_
25-13	5161-5168	receive	_
25-14	5169-5175	weekly	_
25-15	5176-5196	cognitive-behavioral	_
25-16	5197-5204	therapy	_
25-17	5205-5207	to	_
25-18	5208-5214	ensure	_
25-19	5215-5219	that	_
25-20	5220-5223	all	_
25-21	5224-5236	participants	_
25-22	5237-5244	receive	_
25-23	5245-5253	adequate	_
25-24	5254-5266	psychosocial	_
25-25	5267-5274	support	_
25-26	5275-5278	and	_
25-27	5279-5289	monitoring	_
25-28	5290-5291	,	_
25-29	5292-5302	regardless	_
25-30	5303-5305	of	_
25-31	5306-5316	medication	_
25-32	5317-5320	arm	_
25-33	5321-5322	.	_

26-1	5323-5333	Interested	_
26-2	5334-5345	individuals	_
26-3	5346-5349	are	_
26-4	5350-5358	screened	_
26-5	5359-5362	for	_
26-6	5363-5374	eligibility	_
26-7	5375-5377	by	_
26-8	5378-5387	telephone	_
26-9	5388-5390	or	_
26-10	5391-5393	in	_
26-11	5394-5400	person	_
26-12	5401-5402	.	_

27-1	5403-5414	Individuals	_
27-2	5415-5418	who	_
27-3	5419-5423	meet	_
27-4	5424-5443	inclusion/exclusion	_
27-5	5444-5452	criteria	_
27-6	5453-5456	are	_
27-7	5457-5464	invited	_
27-8	5465-5467	to	_
27-9	5468-5472	come	_
27-10	5473-5477	into	_
27-11	5478-5481	the	_
27-12	5482-5488	office	_
27-13	5489-5492	for	_
27-14	5493-5494	a	_
27-15	5495-5508	comprehensive	_
27-16	5509-5517	baseline	_
27-17	5518-5528	assessment	_
27-18	5529-5530	(	_
27-19	5531-5534	see	_
27-20	5535-5540	Table	_
27-21	5541-5542	1	_
27-22	5543-5546	for	_
27-23	5547-5555	measures	_
27-24	5556-5557	)	_
27-25	5558-5559	.	_

28-1	5560-5570	Ineligible	_
28-2	5571-5582	individuals	_
28-3	5583-5586	are	_
28-4	5587-5595	referred	_
28-5	5596-5606	clinically	_
28-6	5607-5610	for	_
28-7	5611-5620	treatment	_
28-8	5621-5622	.	_

29-1	5623-5628	Study	_
29-2	5629-5639	medication	_
29-3	5640-5652	Participants	_
29-4	5653-5656	are	_
29-5	5657-5665	randomly	_
29-6	5666-5674	assigned	_
29-7	5675-5677	in	_
29-8	5678-5679	a	_
29-9	5680-5683	1:1	_
29-10	5684-5690	manner	_
29-11	5691-5693	to	_
29-12	5694-5701	receive	_
29-13	5702-5711	doxazosin	_
29-14	5712-5713	(	_
29-15	5714-5716	16	_
29-16	5717-5723	mg/day	_
29-17	5724-5725	)	_
29-18	5726-5728	or	_
29-19	5729-5736	placebo	_
29-20	5737-5738	.	_

30-1	5739-5742	The	_
30-2	5743-5747	dose	_
30-3	5748-5751	was	_
30-4	5752-5760	selected	_
30-5	5761-5766	based	_
30-6	5767-5769	on	_
30-7	5770-5778	previous	_
30-8	5779-5787	research	_
30-9	5788-5789	.	_

31-1	5790-5795	Study	_
31-2	5796-5806	medication	_
31-3	5807-5810	and	_
31-4	5811-5819	matching	_
31-5	5820-5827	placebo	_
31-6	5828-5831	are	_
31-7	5832-5844	encapsulated	_
31-8	5845-5847	in	_
31-9	5848-5862	standard-sized	_
31-10	5863-5870	gelatin	_
31-11	5871-5879	capsules	_
31-12	5880-5883	and	_
31-13	5884-5887	are	_
31-14	5888-5890	of	_
31-15	5891-5901	sufficient	_
31-16	5902-5909	opacity	_
31-17	5910-5913	and	_
31-18	5914-5919	color	_
31-19	5920-5922	so	_
31-20	5923-5925	as	_
31-21	5926-5929	not	_
31-22	5930-5932	to	_
31-23	5933-5939	reveal	_
31-24	5940-5948	contents	_
31-25	5949-5955	inside	_
31-26	5956-5958	or	_
31-27	5959-5967	disclose	_
31-28	5968-5971	any	_
31-29	5972-5980	possible	_
31-30	5981-5991	difference	_
31-31	5992-5999	between	_
31-32	6000-6007	placebo	_
31-33	6008-6011	and	_
31-34	6012-6018	active	_
31-35	6019-6027	capsules	_
31-36	6028-6029	.	_

32-1	6030-6036	Active	_
32-2	6037-6042	study	_
32-3	6043-6053	medication	_
32-4	6054-6062	capsules	_
32-5	6063-6070	consist	_
32-6	6071-6073	of	_
32-7	6074-6083	USP-grade	_
32-8	6084-6093	doxazosin	_
32-9	6094-6097	and	_
32-10	6098-6100	25	_
32-11	6101-6103	mg	_
32-12	6104-6114	riboflavin	_
32-13	6115-6116	.	_

33-1	6117-6120	All	_
33-2	6121-6126	study	_
33-3	6127-6135	capsules	_
33-4	6136-6143	contain	_
33-5	6144-6152	dextrose	_
33-6	6153-6155	as	_
33-7	6156-6159	the	_
33-8	6160-6165	inert	_
33-9	6166-6173	filling	_
33-10	6174-6179	agent	_
33-11	6180-6183	and	_
33-12	6184-6187	are	_
33-13	6188-6195	brought	_
33-14	6196-6198	to	_
33-15	6199-6205	proper	_
33-16	6206-6213	packing	_
33-17	6214-6219	level	_
33-18	6220-6222	in	_
33-19	6223-6236	color-matched	_
33-20	6237-6238	,	_
33-21	6239-6245	opaque	_
33-22	6246-6247	,	_
33-23	6248-6259	identically	_
33-24	6260-6265	sized	_
33-25	6266-6274	capsules	_
33-26	6275-6276	.	_

34-1	6277-6289	Participants	_
34-2	6290-6293	who	_
34-3	6294-6298	wish	_
34-4	6299-6301	to	_
34-5	6302-6306	take	_
34-6	6307-6308	a	_
34-7	6309-6321	multivitamin	_
34-8	6322-6328	during	_
34-9	6329-6332	the	_
34-10	6333-6342	treatment	_
34-11	6343-6348	phase	_
34-12	6349-6351	of	_
34-13	6352-6355	the	_
34-14	6356-6361	study	_
34-15	6362-6365	are	_
34-16	6366-6371	given	_
34-17	6372-6373	a	_
34-18	6374-6386	multivitamin	_
34-19	6387-6388	(	_
34-20	6389-6398	TriVi-Sol	_
34-21	6399-6400	)	_
34-22	6401-6405	that	_
34-23	6406-6410	does	_
34-24	6411-6414	not	_
34-25	6415-6422	contain	_
34-26	6423-6433	riboflavin	_
34-27	6434-6435	.	_

35-1	6436-6445	Treatment	_
35-2	6446-6456	assignment	_
35-3	6457-6464	follows	_
35-4	6465-6466	a	_
35-5	6467-6478	prearranged	_
35-6	6479-6492	randomization	_
35-7	6493-6499	scheme	_
35-8	6500-6503	and	_
35-9	6504-6506	is	_
35-10	6507-6514	carried	_
35-11	6515-6518	out	_
35-12	6519-6521	by	_
35-13	6522-6523	a	_
35-14	6524-6532	research	_
35-15	6533-6543	pharmacist	_
35-16	6544-6547	not	_
35-17	6548-6556	involved	_
35-18	6557-6559	in	_
35-19	6560-6568	clinical	_
35-20	6569-6579	management	_
35-21	6580-6582	of	_
35-22	6583-6595	participants	_
35-23	6596-6598	in	_
35-24	6599-6604	order	_
35-25	6605-6607	to	_
35-26	6608-6616	preserve	_
35-27	6617-6620	the	_
35-28	6621-6633	double-blind	_
35-29	6634-6640	design	_
35-30	6641-6642	.	_

36-1	6643-6652	Doxazosin	_
36-2	6653-6655	is	_
36-3	6656-6665	initiated	_
36-4	6666-6668	at	_
36-5	6669-6670	1	_
36-6	6671-6677	mg/day	_
36-7	6678-6681	and	_
36-8	6682-6686	then	_
36-9	6687-6695	titrated	_
36-10	6696-6698	up	_
36-11	6699-6701	as	_
36-12	6702-6709	follows	_
36-13	6710-6711	:	_
36-14	6712-6713	2	_
36-15	6714-6716	mg	_
36-16	6717-6719	at	_
36-17	6720-6724	Week	_
36-18	6725-6726	2	_
36-19	6727-6728	;	_
36-20	6729-6730	4	_
36-21	6731-6733	mg	_
36-22	6734-6736	at	_
36-23	6737-6741	Week	_
36-24	6742-6743	3	_
36-25	6744-6745	;	_
36-26	6746-6747	8	_
36-27	6748-6750	mg	_
36-28	6751-6753	at	_
36-29	6754-6758	Week	_
36-30	6759-6760	4	_
36-31	6761-6762	;	_
36-32	6763-6766	and	_
36-33	6767-6771	then	_
36-34	6772-6774	16	_
36-35	6775-6777	mg	_
36-36	6778-6784	during	_
36-37	6785-6790	Weeks	_
36-38	6791-6795	5–12	_
36-39	6796-6797	.	_

37-1	6798-6799	A	_
37-2	6800-6808	downward	_
37-3	6809-6818	titration	_
37-4	6819-6822	for	_
37-5	6823-6829	safety	_
37-6	6830-6836	occurs	_
37-7	6837-6839	at	_
37-8	6840-6843	the	_
37-9	6844-6847	end	_
37-10	6848-6850	of	_
37-11	6851-6855	Week	_
37-12	6856-6858	12	_
37-13	6859-6862	and	_
37-14	6863-6875	participants	_
37-15	6876-6879	are	_
37-16	6880-6888	titrated	_
37-17	6889-6893	down	_
37-18	6894-6896	to	_
37-19	6897-6898	8	_
37-20	6899-6901	mg	_
37-21	6902-6904	on	_
37-22	6905-6908	Day	_
37-23	6909-6910	1	_
37-24	6911-6912	;	_
37-25	6913-6914	6	_
37-26	6915-6917	mg	_
37-27	6918-6920	on	_
37-28	6921-6924	Day	_
37-29	6925-6926	2	_
37-30	6927-6928	;	_
37-31	6929-6930	4	_
37-32	6931-6933	mg	_
37-33	6934-6936	on	_
37-34	6937-6940	Day	_
37-35	6941-6942	3	_
37-36	6943-6944	;	_
37-37	6945-6946	2	_
37-38	6947-6949	mg	_
37-39	6950-6952	on	_
37-40	6953-6956	Day	_
37-41	6957-6958	4	_
37-42	6959-6960	;	_
37-43	6961-6964	and	_
37-44	6965-6966	1	_
37-45	6967-6969	mg	_
37-46	6970-6972	on	_
37-47	6973-6976	Day	_
37-48	6977-6978	5	_
37-49	6979-6980	.	_

38-1	6981-6988	Primary	_
38-2	6989-6996	outcome	_
38-3	6997-7005	measures	_
38-4	7006-7018	Participants	_
38-5	7019-7027	complete	_
38-6	7028-7031	the	_
38-7	7032-7035	CAP	_
38-8	7036-7042	Common	_
38-9	7043-7047	Data	_
38-10	7048-7056	Elements	_
38-11	7057-7064	battery	_
38-12	7065-7066	,	_
38-13	7067-7072	which	_
38-14	7073-7081	includes	_
38-15	7082-7093	demographic	_
38-16	7094-7097	and	_
38-17	7098-7106	military	_
38-18	7107-7114	history	_
38-19	7115-7126	information	_
38-20	7127-7128	,	_
38-21	7129-7140	personality	_
38-22	7141-7142	,	_
38-23	7143-7153	deployment	_
38-24	7154-7160	stress	_
38-25	7161-7162	,	_
38-26	7163-7169	trauma	_
38-27	7170-7171	,	_
38-28	7172-7183	psychiatric	_
38-29	7184-7192	symptoms	_
38-30	7193-7194	,	_
38-31	7195-7204	traumatic	_
38-32	7205-7210	brain	_
38-33	7211-7217	injury	_
38-34	7218-7219	,	_
38-35	7220-7229	substance	_
38-36	7230-7233	use	_
38-37	7234-7235	,	_
38-38	7236-7246	functional	_
38-39	7247-7257	impairment	_
38-40	7258-7259	,	_
38-41	7260-7267	sources	_
38-42	7268-7270	of	_
38-43	7271-7278	support	_
38-44	7279-7280	,	_
38-45	7281-7286	sleep	_
38-46	7287-7297	impairment	_
38-47	7298-7299	,	_
38-48	7300-7304	pain	_
38-49	7305-7306	,	_
38-50	7307-7319	relationship	_
38-51	7320-7331	functioning	_
38-52	7332-7333	,	_
38-53	7334-7337	and	_
38-54	7338-7347	treatment	_
38-55	7348-7359	credibility	_
38-56	7360-7370	expectancy	_
38-57	7371-7372	.	_

39-1	7373-7376	The	_
39-2	7377-7380	CAP	_
39-3	7381-7391	Assessment	_
39-4	7392-7396	Core	_
39-5	7397-7400	has	_
39-6	7401-7410	carefully	_
39-7	7411-7419	reviewed	_
39-8	7420-7423	and	_
39-9	7424-7432	selected	_
39-10	7433-7438	these	_
39-11	7439-7447	measures	_
39-12	7448-7450	to	_
39-13	7451-7457	ensure	_
39-14	7458-7462	that	_
39-15	7463-7467	only	_
39-16	7468-7476	measures	_
39-17	7477-7481	with	_
39-18	7482-7485	the	_
39-19	7486-7493	highest	_
39-20	7494-7500	levels	_
39-21	7501-7503	of	_
39-22	7504-7512	validity	_
39-23	7513-7516	and	_
39-24	7517-7528	reliability	_
39-25	7529-7532	are	_
39-26	7533-7541	included	_
39-27	7542-7544	as	_
39-28	7545-7549	part	_
39-29	7550-7552	of	_
39-30	7553-7556	the	_
39-31	7557-7560	CAP	_
39-32	7561-7567	Common	_
39-33	7568-7572	Data	_
39-34	7573-7581	Elements	_
39-35	7582-7589	battery	_
39-36	7590-7591	.	_

40-1	7592-7595	The	_
40-2	7596-7603	primary	_
40-3	7604-7611	outcome	_
40-4	7612-7620	measures	_
40-5	7621-7624	for	_
40-6	7625-7629	this	_
40-7	7630-7635	study	_
40-8	7636-7639	are	_
40-9	7640-7641	:	_
40-10	7642-7643	(	_
40-11	7644-7645	1	_
40-12	7646-7647	)	_
40-13	7648-7651	the	_
40-14	7652-7658	CAPS-5	_
40-15	7659-7660	,	_
40-16	7661-7662	(	_
40-17	7663-7664	2	_
40-18	7665-7666	)	_
40-19	7667-7670	the	_
40-20	7671-7676	PCL-5	_
40-21	7677-7678	,	_
40-22	7679-7682	and	_
40-23	7683-7684	(	_
40-24	7685-7686	3	_
40-25	7687-7688	)	_
40-26	7689-7692	the	_
40-27	7693-7697	TLFB	_
40-28	7698-7699	.	_

41-1	7700-7703	The	_
41-2	7704-7710	CAPS-5	_
41-3	7711-7713	is	_
41-4	7714-7715	a	_
41-5	7716-7730	semistructured	_
41-6	7731-7740	interview	_
41-7	7741-7745	used	_
41-8	7746-7748	to	_
41-9	7749-7755	assess	_
41-10	7756-7760	PTSD	_
41-11	7761-7770	diagnosis	_
41-12	7771-7774	and	_
41-13	7775-7782	symptom	_
41-14	7783-7791	severity	_
41-15	7792-7793	.	_

42-1	7794-7797	The	_
42-2	7798-7804	CAPS-5	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder
42-3	7805-7807	is	_
42-4	7808-7813	rated	_
42-5	7814-7816	on	_
42-6	7817-7818	a	_
42-7	7819-7826	5-point	_
42-8	7827-7832	scale	_
42-9	7833-7834	(	_
42-10	7835-7836	0	_
42-11	7837-7838	=	_
42-12	7839-7845	absent	_
42-13	7846-7848	to	_
42-14	7849-7850	4	_
42-15	7851-7852	=	_
42-16	7853-7875	extreme/incapacitating	_
42-17	7876-7877	)	_
42-18	7878-7882	with	_
42-19	7883-7884	a	_
42-20	7885-7890	total	_
42-21	7891-7896	score	_
42-22	7897-7904	ranging	_
42-23	7905-7909	from	_
42-24	7910-7911	0	_
42-25	7912-7914	to	_
42-26	7915-7917	80	_
42-27	7918-7919	.	_

43-1	7920-7922	In	_
43-2	7923-7927	this	_
43-3	7928-7933	study	_
43-4	7934-7935	,	_
43-5	7936-7939	the	_
43-6	7940-7946	CAPS-5	_
43-7	7947-7949	is	_
43-8	7950-7962	administered	_
43-9	7963-7965	by	_
43-10	7966-7977	independent	_
43-11	7978-7988	evaluators	_
43-12	7989-7990	(	_
43-13	7991-7993	IE	_
43-14	7994-7995	)	_
43-15	7996-8003	trained	_
43-16	8004-8007	and	_
43-17	8008-8017	certified	_
43-18	8018-8020	by	_
43-19	8021-8024	the	_
43-20	8025-8028	CAP	_
43-21	8029-8039	Assessment	_
43-22	8040-8044	Core	_
43-23	8045-8048	and	_
43-24	8049-8054	blind	_
43-25	8055-8057	to	_
43-26	8058-8067	treatment	_
43-27	8068-8074	status	_
43-28	8075-8076	.	_

44-1	8077-8080	The	_
44-2	8081-8086	PCL-5	_
44-3	8087-8089	is	_
44-4	8090-8091	a	_
44-5	8092-8099	20-item	_
44-6	8100-8101	,	_
44-7	8102-8113	self-report	_
44-8	8114-8121	measure	_
44-9	8122-8126	that	_
44-10	8127-8135	assesses	_
44-11	8136-8140	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
44-12	8141-8149	severity	_
44-13	8150-8155	using	_
44-14	8156-8157	a	_
44-15	8158-8164	Likert	_
44-16	8165-8170	scale	_
44-17	8171-8172	(	_
44-18	8173-8174	0	_
44-19	8175-8176	=	_
44-20	8177-8180	not	_
44-21	8181-8183	at	_
44-22	8184-8187	all	_
44-23	8188-8190	to	_
44-24	8191-8192	4	_
44-25	8193-8194	=	_
44-26	8195-8204	extremely	_
44-27	8205-8206	)	_
44-28	8207-8208	.	_

45-1	8209-8216	Finally	_
45-2	8217-8218	,	_
45-3	8219-8222	the	_
45-4	8223-8227	TLFB	_
45-5	8228-8235	obtains	_
45-6	8236-8249	retrospective	_
45-7	8250-8261	self-report	_
45-8	8262-8264	of	_
45-9	8265-8274	substance	_
45-10	8275-8278	use	_
45-11	8279-8281	by	_
45-12	8282-8287	using	_
45-13	8288-8289	a	_
45-14	8290-8298	calendar	_
45-15	8299-8302	and	_
45-16	8303-8309	memory	_
45-17	8310-8317	prompts	_
45-18	8318-8320	to	_
45-19	8321-8330	stimulate	_
45-20	8331-8337	recall	_
45-21	8338-8339	.	_

46-1	8340-8348	Quantity	_
46-2	8349-8352	and	_
46-3	8353-8362	frequency	_
46-4	8363-8374	assessments	_
46-5	8375-8378	are	_
46-6	8379-8383	made	_
46-7	8384-8389	using	_
46-8	8390-8394	this	_
46-9	8395-8405	instrument	_
46-10	8406-8407	(	_
46-11	8408-8412	e.g.	_
46-12	8413-8414	,	_
46-13	8415-8420	total	_
46-14	8421-8427	number	_
46-15	8428-8430	of	_
46-16	8431-8439	standard	_
46-17	8440-8445	drink	_
46-18	8446-8451	units	_
46-19	8452-8453	,	_
46-20	8454-8461	percent	_
46-21	8462-8464	of	_
46-22	8465-8469	days	_
46-23	8470-8475	using	_
46-24	8476-8477	)	_
46-25	8478-8480	as	_
46-26	8481-8485	well	_
46-27	8486-8488	as	_
46-28	8489-8499	abstinence	_
46-29	8500-8501	(	_
46-30	8502-8508	yes/no	_
46-31	8509-8510	)	_
46-32	8511-8512	.	_

47-1	8513-8517	TLFB	_
47-2	8518-8524	yields	_
47-3	8525-8537	consistently	_
47-4	8538-8542	high	_
47-5	8543-8554	test-retest	_
47-6	8555-8567	correlations	_
47-7	8568-8571	and	_
47-8	8572-8582	correlates	_
47-9	8583-8587	well	_
47-10	8588-8592	with	_
47-11	8593-8598	other	_
47-12	8599-8611	self-reports	_
47-13	8612-8615	and	_
47-14	8616-8626	collateral	_
47-15	8627-8634	reports	_
47-16	8635-8636	.	_

48-1	8637-8640	The	_
48-2	8641-8645	TLFB	_
48-3	8646-8654	assesses	_
48-4	8655-8664	frequency	_
48-5	8665-8668	and	_
48-6	8669-8675	amount	_
48-7	8676-8678	of	_
48-8	8679-8688	substance	_
48-9	8689-8692	use	_
48-10	8693-8696	for	_
48-11	8697-8699	60	_
48-12	8700-8704	days	_
48-13	8705-8710	prior	_
48-14	8711-8713	to	_
48-15	8714-8719	study	_
48-16	8720-8725	entry	_
48-17	8726-8727	,	_
48-18	8728-8734	during	_
48-19	8735-8738	the	_
48-20	8739-8741	12	_
48-21	8742-8747	weeks	_
48-22	8748-8750	of	_
48-23	8751-8760	treatment	_
48-24	8761-8762	,	_
48-25	8763-8766	and	_
48-26	8767-8769	at	_
48-27	8770-8779	follow-up	_
48-28	8780-8781	.	_

49-1	8782-8791	Secondary	_
49-2	8792-8799	outcome	_
49-3	8800-8808	measures	_
49-4	8809-8818	Secondary	_
49-5	8819-8827	outcomes	_
49-6	8828-8835	related	_
49-7	8836-8838	to	_
49-8	8839-8846	alcohol	_
49-9	8847-8854	craving	_
49-10	8855-8858	and	_
49-11	8859-8875	characterization	_
49-12	8876-8878	of	_
49-13	8879-8882	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
49-14	8883-8886	are	_
49-15	8887-8895	measured	_
49-16	8896-8898	by	_
49-17	8899-8904	using	_
49-18	8905-8908	the	_
49-19	8909-8918	Obsessive	http://maven.renci.org/NeuroBridge/neurobridge#ObsessiveCompulsiveDisorder
49-20	8919-8929	Compulsive	http://maven.renci.org/NeuroBridge/neurobridge#ObsessiveCompulsiveDisorder
49-21	8930-8938	Drinking	http://maven.renci.org/NeuroBridge/neurobridge#ObsessiveCompulsiveDisorder
49-22	8939-8944	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ObsessiveCompulsiveDisorder
49-23	8945-8946	(	http://maven.renci.org/NeuroBridge/neurobridge#ObsessiveCompulsiveDisorder
49-24	8947-8951	OCDS	http://maven.renci.org/NeuroBridge/neurobridge#ObsessiveCompulsiveDisorder
49-25	8952-8953	)	http://maven.renci.org/NeuroBridge/neurobridge#ObsessiveCompulsiveDisorder
49-26	8954-8955	,	_
49-27	8956-8961	Brief	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
49-28	8962-8971	Addiction	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
49-29	8972-8979	Monitor	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
49-30	8980-8981	(	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
49-31	8982-8985	BAM	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
49-32	8986-8987	)	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
49-33	8988-8989	,	_
49-34	8990-8995	ethyl	_
49-35	8996-9007	glucuronide	_
49-36	9008-9009	(	_
49-37	9010-9011	a	_
49-38	9012-9022	conjugated	_
49-39	9023-9030	alcohol	_
49-40	9031-9041	metabolite	_
49-41	9042-9051	biomarker	_
49-42	9052-9054	of	_
49-43	9055-9061	recent	_
49-44	9062-9069	alcohol	_
49-45	9070-9081	consumption	_
49-46	9082-9083	)	_
49-47	9084-9085	,	_
49-48	9086-9089	and	_
49-49	9090-9096	family	_
49-50	9097-9104	history	_
49-51	9105-9107	of	_
49-52	9108-9117	addiction	_
49-53	9118-9123	using	_
49-54	9124-9127	the	_
49-55	9128-9137	Addiction	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
49-56	9138-9146	Severity	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
49-57	9147-9152	Index	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
49-58	9153-9159	family	_
49-59	9160-9167	history	_
49-60	9168-9175	section	_
49-61	9176-9177	.	_

50-1	9178-9186	Symptoms	_
50-2	9187-9189	of	_
50-3	9190-9200	depression	_
50-4	9201-9202	,	_
50-5	9203-9214	suicidality	_
50-6	9215-9216	,	_
50-7	9217-9229	psychosocial	_
50-8	9230-9241	functioning	_
50-9	9242-9243	,	_
50-10	9244-9247	and	_
50-11	9248-9257	emotional	_
50-12	9258-9268	regulation	_
50-13	9269-9273	will	_
50-14	9274-9276	be	_
50-15	9277-9285	assessed	_
50-16	9286-9291	using	_
50-17	9292-9295	the	_
50-18	9296-9310	well-validated	_
50-19	9311-9322	instruments	_
50-20	9323-9328	shown	_
50-21	9329-9331	in	_
50-22	9332-9337	Table	_
50-23	9338-9339	1	_
50-24	9340-9341	.	_

51-1	9342-9349	Related	_
51-2	9350-9357	aspects	_
51-3	9358-9360	of	_
51-4	9361-9365	PTSD	_
51-5	9366-9374	severity	_
51-6	9375-9379	such	_
51-7	9380-9382	as	_
51-8	9383-9388	sleep	_
51-9	9389-9400	disturbance	_
51-10	9401-9402	,	_
51-11	9403-9412	frequency	_
51-12	9413-9415	of	_
51-13	9416-9426	nightmares	_
51-14	9427-9428	,	_
51-15	9429-9432	and	_
51-16	9433-9441	insomnia	_
51-17	9442-9446	will	_
51-18	9447-9451	also	_
51-19	9452-9454	be	_
51-20	9455-9464	regularly	_
51-21	9465-9474	monitored	_
51-22	9475-9476	(	_
51-23	9477-9480	see	_
51-24	9481-9486	Table	_
51-25	9487-9488	1	_
51-26	9489-9490	)	_
51-27	9491-9492	.	_

52-1	9493-9505	Neuroimaging	_
52-2	9506-9515	component	_
52-3	9516-9518	In	_
52-4	9519-9527	addition	_
52-5	9528-9530	to	_
52-6	9531-9538	testing	_
52-7	9539-9542	the	_
52-8	9543-9549	safety	_
52-9	9550-9553	and	_
52-10	9554-9562	efficacy	_
52-11	9563-9565	of	_
52-12	9566-9575	doxazosin	_
52-13	9576-9577	,	_
52-14	9578-9582	this	_
52-15	9583-9588	study	_
52-16	9589-9593	will	_
52-17	9594-9605	investigate	_
52-18	9606-9612	neural	_
52-19	9613-9622	circuitry	_
52-20	9623-9633	underlying	_
52-21	9634-9642	comorbid	_
52-22	9643-9651	PTSD/AUD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
52-23	9652-9653	.	_

53-1	9654-9658	This	_
53-2	9659-9670	information	_
53-3	9671-9674	may	_
53-4	9675-9679	help	_
53-5	9680-9686	inform	_
53-6	9687-9690	the	_
53-7	9691-9700	selection	_
53-8	9701-9703	of	_
53-9	9704-9713	treatment	_
53-10	9714-9721	targets	_
53-11	9722-9725	and	_
53-12	9726-9731	novel	_
53-13	9732-9743	therapeutic	_
53-14	9744-9750	agents	_
53-15	9751-9753	in	_
53-16	9754-9760	future	_
53-17	9761-9769	research	_
53-18	9770-9771	.	_

54-1	9772-9774	To	_
54-2	9775-9779	that	_
54-3	9780-9783	end	_
54-4	9784-9785	,	_
54-5	9786-9798	neuroimaging	_
54-6	9799-9803	data	_
54-7	9804-9806	is	_
54-8	9807-9815	acquired	_
54-9	9816-9827	immediately	_
54-10	9828-9833	prior	_
54-11	9834-9836	to	_
54-12	9837-9847	medication	_
54-13	9848-9858	initiation	_
54-14	9859-9862	and	_
54-15	9863-9873	medication	_
54-16	9874-9889	discontinuation	_
54-17	9890-9892	on	_
54-18	9893-9896	all	_
54-19	9897-9905	eligible	_
54-20	9906-9918	participants	_
54-21	9919-9920	.	_

55-1	9921-9923	As	_
55-2	9924-9935	illustrated	_
55-3	9936-9938	in	_
55-4	9939-9942	Fig	_
55-5	9943-9944	.	_

56-1	9945-9946	2	_
56-2	9947-9948	,	_
56-3	9949-9958	following	_
56-4	9959-9962	the	_
56-5	9963-9970	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
56-6	9971-9976	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
56-7	9977-9982	scans	_
56-8	9983-9984	,	_
56-9	9985-9997	participants	_
56-10	9998-10001	are	_
56-11	10002-10009	exposed	_
56-12	10010-10012	to	_
56-13	10013-10020	neutral	_
56-14	10021-10022	,	_
56-15	10023-10029	trauma	_
56-16	10030-10031	,	_
56-17	10032-10035	and	_
56-18	10036-10043	alcohol	_
56-19	10044-10048	cues	_
56-20	10049-10050	.	_

57-1	10051-10053	To	_
57-2	10054-10062	minimize	_
57-3	10063-10072	potential	_
57-4	10073-10083	carry-over	_
57-5	10084-10091	effects	_
57-6	10092-10093	,	_
57-7	10094-10097	the	_
57-8	10098-10104	trauma	_
57-9	10105-10108	and	_
57-10	10109-10116	alcohol	_
57-11	10117-10121	cues	_
57-12	10122-10125	are	_
57-13	10126-10141	counterbalanced	_
57-14	10142-10143	.	_

58-1	10144-10147	For	_
58-2	10148-10152	both	_
58-3	10153-10160	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
58-4	10161-10166	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
58-5	10167-10170	and	_
58-6	10171-10175	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
58-7	10176-10180	runs	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
58-8	10181-10182	,	_
58-9	10183-10185	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
58-10	10186-10187	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
58-11	10188-10197	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
58-12	10198-10211	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
58-13	10212-10218	planar	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
58-14	10219-10225	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
58-15	10226-10227	(	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
58-16	10228-10231	EPI	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
58-17	10232-10233	)	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
58-18	10234-10237	are	_
58-19	10238-10246	acquired	_
58-20	10247-10251	with	_
58-21	10252-10255	the	_
58-22	10256-10265	following	_
58-23	10266-10276	parameters	_
58-24	10277-10278	:	_
58-25	10279-10281	TR	_
58-26	10282-10283	=	_
58-27	10284-10288	1100	_
58-28	10289-10291	ms	_
58-29	10292-10293	,	_
58-30	10294-10296	TE	_
58-31	10297-10298	=	_
58-32	10299-10301	30	_
58-33	10302-10304	ms	_
58-34	10305-10306	,	_
58-35	10307-10311	flip	_
58-36	10312-10317	angle	_
58-37	10318-10319	=	_
58-38	10320-10323	65°	_
58-39	10324-10325	,	_
58-40	10326-10330	ipat	_
58-41	10331-10337	factor	_
58-42	10338-10339	=	_
58-43	10340-10341	3	_
58-44	10342-10343	,	_
58-45	10344-10350	matrix	_
58-46	10351-10353	64	_
58-47	10354-10355	×	_
58-48	10356-10358	64	_
58-49	10359-10360	,	_
58-50	10361-10366	field	_
58-51	10367-10369	of	_
58-52	10370-10374	view	_
58-53	10375-10376	=	_
58-54	10377-10381	19.2	_
58-55	10382-10384	cm	_
58-56	10385-10386	,	_
58-57	10387-10392	slice	_
58-58	10393-10402	thickness	_
58-59	10403-10404	=	_
58-60	10405-10408	3.0	_
58-61	10409-10411	mm	_
58-62	10412-10416	with	_
58-63	10417-10419	no	_
58-64	10420-10423	gap	_
58-65	10424-10425	,	_
58-66	10426-10430	with	_
58-67	10431-10433	48	_
58-68	10434-10440	slices	_
58-69	10441-10443	to	_
58-70	10444-10449	cover	_
58-71	10450-10453	the	_
58-72	10454-10460	entire	_
58-73	10461-10466	brain	_
58-74	10467-10468	.	_

59-1	10469-10472	All	_
59-2	10473-10478	scans	_
59-3	10479-10482	are	_
59-4	10483-10492	conducted	_
59-5	10493-10495	at	_
59-6	10496-10499	the	_
59-7	10500-10504	MUSC	_
59-8	10505-10511	Center	_
59-9	10512-10515	for	_
59-10	10516-10526	Biomedical	_
59-11	10527-10534	Imaging	_
59-12	10535-10536	,	_
59-13	10537-10542	which	_
59-14	10543-10549	houses	_
59-15	10550-10551	a	_
59-16	10552-10559	Siemens	_
59-17	10560-10561	3	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
59-18	10562-10563	T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
59-19	10564-10570	Prisma	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
59-20	10571-10574	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
59-21	10575-10582	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
59-22	10583-10584	(	_
59-23	10585-10592	Siemens	_
59-24	10593-10600	Medical	_
59-25	10601-10602	,	_
59-26	10603-10611	Erlangen	_
59-27	10612-10613	,	_
59-28	10614-10621	Germany	_
59-29	10622-10623	)	_
59-30	10624-10625	.	_

60-1	10626-10630	Data	_
60-2	10631-10639	analytic	_
60-3	10640-10644	plan	_
60-4	10645-10652	General	_
60-5	10653-10667	considerations	_
60-6	10668-10671	and	_
60-7	10672-10677	power	_
60-8	10678-10686	Analyses	_
60-9	10687-10691	will	_
60-10	10692-10694	be	_
60-11	10695-10704	performed	_
60-12	10705-10707	on	_
60-13	10708-10711	the	_
60-14	10712-10727	intent-to-treat	_
60-15	10728-10729	(	_
60-16	10730-10733	ITT	_
60-17	10734-10735	)	_
60-18	10736-10742	sample	_
60-19	10743-10753	consisting	_
60-20	10754-10756	of	_
60-21	10757-10760	all	_
60-22	10761-10771	randomized	_
60-23	10772-10784	participants	_
60-24	10785-10788	who	_
60-25	10789-10796	provide	_
60-26	10797-10800	any	_
60-27	10801-10808	outcome	_
60-28	10809-10813	data	_
60-29	10814-10815	.	_

61-1	10816-10824	Baseline	_
61-2	10825-10833	clinical	_
61-3	10834-10837	and	_
61-4	10838-10849	demographic	_
61-5	10850-10865	characteristics	_
61-6	10866-10869	are	_
61-7	10870-10879	collected	_
61-8	10880-10881	,	_
61-9	10882-10885	and	_
61-10	10886-10895	contrasts	_
61-11	10896-10900	will	_
61-12	10901-10903	be	_
61-13	10904-10913	performed	_
61-14	10914-10921	between	_
61-15	10922-10931	treatment	_
61-16	10932-10938	groups	_
61-17	10939-10940	.	_

62-1	10941-10945	This	_
62-2	10946-10951	study	_
62-3	10952-10954	is	_
62-4	10955-10962	powered	_
62-5	10963-10965	to	_
62-6	10966-10974	estimate	_
62-7	10975-10978	the	_
62-8	10979-10986	effects	_
62-9	10987-10989	of	_
62-10	10990-10999	doxazosin	_
62-11	11000-11002	on	_
62-12	11003-11014	significant	_
62-13	11015-11024	reduction	_
62-14	11025-11027	in	_
62-15	11028-11032	PTSD	_
62-16	11033-11041	symptoms	_
62-17	11042-11044	at	_
62-18	11045-11048	the	_
62-19	11049-11052	end	_
62-20	11053-11055	of	_
62-21	11056-11065	treatment	_
62-22	11066-11067	(	_
62-23	11068-11071	see	_
62-24	11072-11082	Hypothesis	_
62-25	11083-11084	1	_
62-26	11085-11086	)	_
62-27	11087-11088	,	_
62-28	11089-11092	and	_
62-29	11093-11102	increased	_
62-30	11103-11113	abstinence	_
62-31	11114-11119	rates	_
62-32	11120-11122	at	_
62-33	11123-11126	the	_
62-34	11127-11130	end	_
62-35	11131-11133	of	_
62-36	11134-11143	treatment	_
62-37	11144-11145	(	_
62-38	11146-11156	Hypothesis	_
62-39	11157-11158	2	_
62-40	11159-11160	)	_
62-41	11161-11162	.	_

63-1	11163-11170	Placebo	_
63-2	11171-11176	rates	_
63-3	11177-11179	of	_
63-4	11180-11189	reduction	_
63-5	11190-11192	in	_
63-6	11193-11197	CAPS	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalograph
63-7	11198-11204	scores	_
63-8	11205-11208	are	_
63-9	11209-11223	conservatively	_
63-10	11224-11233	estimated	_
63-11	11234-11236	to	_
63-12	11237-11239	be	_
63-13	11240-11242	20	_
63-14	11243-11244	%	_
63-15	11245-11246	.	_

64-1	11247-11249	In	_
64-2	11250-11251	a	_
64-3	11252-11257	small	_
64-4	11258-11263	pilot	_
64-5	11264-11269	study	_
64-6	11270-11271	,	_
64-7	11272-11274	De	_
64-8	11275-11279	Jong	_
64-9	11280-11282	et	_
64-10	11283-11285	al	_
64-11	11286-11287	.	_

65-1	11288-11293	found	_
65-2	11294-11297	~31	_
65-3	11298-11299	%	_
65-4	11300-11309	reduction	_
65-5	11310-11312	in	_
65-6	11313-11317	CAPS	_
65-7	11318-11323	total	_
65-8	11324-11330	scores	_
65-9	11331-11336	using	_
65-10	11337-11346	doxazosin	_
65-11	11347-11348	.	_

66-1	11349-11350	A	_
66-2	11351-11357	sample	_
66-3	11358-11360	of	_
66-4	11361-11364	100	_
66-5	11365-11377	participants	_
66-6	11378-11382	will	_
66-7	11383-11390	provide	_
66-8	11391-11393	80	_
66-9	11394-11395	%	_
66-10	11396-11401	power	_
66-11	11402-11406	with	_
66-12	11407-11408	a	_
66-13	11409-11413	0.05	_
66-14	11414-11418	type	_
66-15	11419-11420	1	_
66-16	11421-11426	error	_
66-17	11427-11431	rate	_
66-18	11432-11434	to	_
66-19	11435-11441	detect	_
66-20	11442-11443	a	_
66-21	11444-11454	difference	_
66-22	11455-11457	in	_
66-23	11458-11461	the	_
66-24	11462-11471	reduction	_
66-25	11472-11474	of	_
66-26	11475-11479	CAPS	_
66-27	11480-11486	scores	_
66-28	11487-11494	between	_
66-29	11495-11504	doxazosin	_
66-30	11505-11506	(	_
66-31	11507-11509	31	_
66-32	11510-11511	±	_
66-33	11512-11514	20	_
66-34	11515-11516	%	_
66-35	11517-11518	)	_
66-36	11519-11522	and	_
66-37	11523-11530	placebo	_
66-38	11531-11532	(	_
66-39	11533-11535	20	_
66-40	11536-11537	±	_
66-41	11538-11540	20	_
66-42	11541-11542	%	_
66-43	11543-11544	)	_
66-44	11545-11546	.	_

67-1	11547-11554	Placebo	_
67-2	11555-11560	rates	_
67-3	11561-11563	of	_
67-4	11564-11574	abstinence	_
67-5	11575-11578	are	_
67-6	11579-11588	estimated	_
67-7	11589-11593	from	_
67-8	11594-11605	established	_
67-9	11606-11618	double-blind	_
67-10	11619-11620	,	_
67-11	11621-11639	placebo-controlled	_
67-12	11640-11646	trials	_
67-13	11647-11648	.	_

68-1	11649-11659	Continuous	_
68-2	11660-11670	abstinence	_
68-3	11671-11675	from	_
68-4	11676-11681	weeks	_
68-5	11682-11686	9–12	_
68-6	11687-11689	is	_
68-7	11690-11698	observed	_
68-8	11699-11701	in	_
68-9	11702-11707	10–15	_
68-10	11708-11709	%	_
68-11	11710-11712	of	_
68-12	11713-11722	treatment	_
68-13	11723-11730	seekers	_
68-14	11731-11738	without	_
68-15	11739-11751	co-occurring	_
68-16	11752-11756	PTSD	_
68-17	11757-11759	so	_
68-18	11760-11762	we	_
68-19	11763-11773	anticipate	_
68-20	11774-11776	an	_
68-21	11777-11787	attenuated	_
68-22	11788-11792	rate	_
68-23	11793-11795	of	_
68-24	11796-11800	5–10	_
68-25	11801-11802	%	_
68-26	11803-11805	in	_
68-27	11806-11809	the	_
68-28	11810-11817	placebo	_
68-29	11818-11823	group	_
68-30	11824-11825	.	_

69-1	11826-11834	Although	_
69-2	11835-11840	there	_
69-3	11841-11843	is	_
69-4	11844-11851	limited	_
69-5	11852-11863	information	_
69-6	11864-11866	on	_
69-7	11867-11870	the	_
69-8	11871-11884	effectiveness	_
69-9	11885-11887	of	_
69-10	11888-11897	doxazosin	_
69-11	11898-11900	in	_
69-12	11901-11904	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
69-13	11905-11906	,	_
69-14	11907-11908	a	_
69-15	11909-11915	sample	_
69-16	11916-11918	of	_
69-17	11919-11922	100	_
69-18	11923-11935	participants	_
69-19	11936-11937	(	_
69-20	11938-11940	50	_
69-21	11941-11943	in	_
69-22	11944-11948	each	_
69-23	11949-11952	arm	_
69-24	11953-11954	)	_
69-25	11955-11959	will	_
69-26	11960-11967	provide	_
69-27	11968-11976	adequate	_
69-28	11977-11982	power	_
69-29	11983-11985	to	_
69-30	11986-11992	detect	_
69-31	11993-11995	an	_
69-32	11996-12006	abstinence	_
69-33	12007-12011	rate	_
69-34	12012-12014	as	_
69-35	12015-12018	low	_
69-36	12019-12021	as	_
69-37	12022-12024	32	_
69-38	12025-12026	%	_
69-39	12027-12029	in	_
69-40	12030-12033	the	_
69-41	12034-12043	doxazosin	_
69-42	12044-12049	group	_
69-43	12050-12054	when	_
69-44	12055-12058	the	_
69-45	12059-12066	placebo	_
69-46	12067-12076	cessation	_
69-47	12077-12081	rate	_
69-48	12082-12084	is	_
69-49	12085-12087	10	_
69-50	12088-12089	%	_
69-51	12090-12091	,	_
69-52	12092-12095	and	_
69-53	12096-12098	as	_
69-54	12099-12102	low	_
69-55	12103-12105	as	_
69-56	12106-12108	23	_
69-57	12109-12110	%	_
69-58	12111-12115	when	_
69-59	12116-12119	the	_
69-60	12120-12127	placebo	_
69-61	12128-12132	rate	_
69-62	12133-12135	is	_
69-63	12136-12137	5	_
69-64	12138-12139	%	_
69-65	12140-12141	.	_

70-1	12142-12145	Due	_
70-2	12146-12148	to	_
70-3	12149-12152	the	_
70-4	12153-12159	nature	_
70-5	12160-12162	of	_
70-6	12163-12166	the	_
70-7	12167-12172	study	_
70-8	12173-12183	population	_
70-9	12184-12185	,	_
70-10	12186-12188	we	_
70-11	12189-12199	anticipate	_
70-12	12200-12203	~30	_
70-13	12204-12205	%	_
70-14	12206-12213	dropout	_
70-15	12214-12218	rate	_
70-16	12219-12220	;	_
70-17	12221-12225	thus	_
70-18	12226-12227	,	_
70-19	12228-12231	the	_
70-20	12232-12238	number	_
70-21	12239-12241	of	_
70-22	12242-12250	subjects	_
70-23	12251-12261	randomized	_
70-24	12262-12264	is	_
70-25	12265-12273	inflated	_
70-26	12274-12276	to	_
70-27	12277-12280	144	_
70-28	12281-12285	with	_
70-29	12286-12288	72	_
70-30	12289-12301	participants	_
70-31	12302-12312	randomized	_
70-32	12313-12315	to	_
70-33	12316-12320	each	_
70-34	12321-12330	treatment	_
70-35	12331-12334	arm	_
70-36	12335-12337	of	_
70-37	12338-12341	the	_
70-38	12342-12347	study	_
70-39	12348-12349	.	_

71-1	12350-12358	Clinical	_
71-2	12359-12367	outcomes	_
71-3	12368-12370	To	_
71-4	12371-12375	test	_
71-5	12376-12386	hypothesis	_
71-6	12387-12388	1	_
71-7	12389-12393	that	_
71-8	12394-12406	participants	_
71-9	12407-12410	who	_
71-10	12411-12418	receive	_
71-11	12419-12428	doxazosin	_
71-12	12429-12430	,	_
71-13	12431-12433	as	_
71-14	12434-12442	compared	_
71-15	12443-12445	to	_
71-16	12446-12453	placebo	_
71-17	12454-12455	,	_
71-18	12456-12460	will	_
71-19	12461-12469	evidence	_
71-20	12470-12483	significantly	_
71-21	12484-12491	greater	_
71-22	12492-12502	reductions	_
71-23	12503-12505	in	_
71-24	12506-12510	PTSD	_
71-25	12511-12519	severity	_
71-26	12520-12521	,	_
71-27	12522-12532	restricted	_
71-28	12533-12540	maximum	_
71-29	12541-12551	likelihood	_
71-30	12552-12553	(	_
71-31	12554-12558	REML	_
71-32	12559-12560	)	_
71-33	12561-12568	methods	_
71-34	12569-12573	will	_
71-35	12574-12576	be	_
71-36	12577-12581	used	_
71-37	12582-12584	to	_
71-38	12585-12593	estimate	_
71-39	12594-12597	the	_
71-40	12598-12603	fixed	_
71-41	12604-12611	effects	_
71-42	12612-12615	and	_
71-43	12616-12624	variance	_
71-44	12625-12635	components	_
71-45	12636-12637	,	_
71-46	12638-12641	and	_
71-47	12642-12652	modelbased	_
71-48	12653-12662	treatment	_
71-49	12663-12669	effect	_
71-50	12670-12679	estimates	_
71-51	12680-12684	will	_
71-52	12685-12687	be	_
71-53	12688-12692	used	_
71-54	12693-12695	to	_
71-55	12696-12705	construct	_
71-56	12706-12711	group	_
71-57	12712-12717	level	_
71-58	12718-12723	tests	_
71-59	12724-12728	over	_
71-60	12729-12733	time	_
71-61	12734-12735	.	_

72-1	12736-12738	To	_
72-2	12739-12743	test	_
72-3	12744-12754	hypothesis	_
72-4	12755-12756	2	_
72-5	12757-12761	that	_
72-6	12762-12774	participants	_
72-7	12775-12778	who	_
72-8	12779-12786	receive	_
72-9	12787-12796	doxazosin	_
72-10	12797-12798	,	_
72-11	12799-12801	as	_
72-12	12802-12810	compared	_
72-13	12811-12813	to	_
72-14	12814-12821	placebo	_
72-15	12822-12823	,	_
72-16	12824-12828	will	_
72-17	12829-12837	evidence	_
72-18	12838-12851	significantly	_
72-19	12852-12859	greater	_
72-20	12860-12870	reductions	_
72-21	12871-12873	in	_
72-22	12874-12877	AUD	_
72-23	12878-12886	severity	_
72-24	12887-12888	,	_
72-25	12889-12897	logistic	_
72-26	12898-12908	regression	_
72-27	12909-12917	analysis	_
72-28	12918-12922	will	_
72-29	12923-12925	be	_
72-30	12926-12930	used	_
72-31	12931-12933	to	_
72-32	12934-12941	examine	_
72-33	12942-12947	rates	_
72-34	12948-12950	of	_
72-35	12951-12961	abstinence	_
72-36	12962-12963	.	_

73-1	12964-12970	Weekly	_
73-2	12971-12976	point	_
73-3	12977-12987	prevalence	_
73-4	12988-12998	abstinence	_
73-5	12999-13003	will	_
73-6	13004-13006	be	_
73-7	13007-13015	examined	_
73-8	13016-13021	using	_
73-9	13022-13033	generalized	_
73-10	13034-13040	linear	_
73-11	13041-13047	models	_
73-12	13048-13053	under	_
73-13	13054-13055	a	_
73-14	13056-13067	generalized	_
73-15	13068-13078	estimating	_
73-16	13079-13088	equations	_
73-17	13089-13090	(	_
73-18	13091-13094	GEE	_
73-19	13095-13096	)	_
73-20	13097-13106	framework	_
73-21	13107-13108	.	_

74-1	13109-13115	Weekly	_
74-2	13116-13126	abstinence	_
74-3	13127-13128	(	_
74-4	13129-13135	yes/no	_
74-5	13136-13137	)	_
74-6	13138-13140	as	_
74-7	13141-13145	well	_
74-8	13146-13148	as	_
74-9	13149-13156	amounts	_
74-10	13157-13159	of	_
74-11	13160-13167	alcohol	_
74-12	13168-13171	use	_
74-13	13172-13173	(	_
74-14	13174-13182	standard	_
74-15	13183-13188	drink	_
74-16	13189-13194	units	_
74-17	13195-13196	)	_
74-18	13197-13201	will	_
74-19	13202-13204	be	_
74-20	13205-13213	examined	_
74-21	13214-13218	over	_
74-22	13219-13223	time	_
74-23	13224-13226	to	_
74-24	13227-13236	determine	_
74-25	13237-13239	if	_
74-26	13240-13249	treatment	_
74-27	13250-13252	is	_
74-28	13253-13262	effective	_
74-29	13263-13265	in	_
74-30	13266-13274	reducing	_
74-31	13275-13282	alcohol	_
74-32	13283-13294	consumption	_
74-33	13295-13299	when	_
74-34	13300-13310	abstinence	_
74-35	13311-13313	is	_
74-36	13314-13317	not	_
74-37	13318-13326	achieved	_
74-38	13327-13328	.	_

75-1	13329-13341	Neuroimaging	_
75-2	13342-13350	outcomes	_
75-3	13351-13353	We	_
75-4	13354-13358	will	_
75-5	13359-13366	measure	_
75-6	13367-13377	functional	_
75-7	13378-13390	connectivity	_
75-8	13391-13396	using	_
75-9	13397-13398	a	_
75-10	13399-13418	psychophysiological	_
75-11	13419-13430	interaction	_
75-12	13431-13432	(	_
75-13	13433-13436	PPI	_
75-14	13437-13438	)	_
75-15	13439-13449	seed-based	_
75-16	13450-13458	approach	_
75-17	13459-13460	.	_

76-1	13461-13464	PPI	_
76-2	13465-13467	is	_
76-3	13468-13469	a	_
76-4	13470-13476	method	_
76-5	13477-13480	for	_
76-6	13481-13494	investigating	_
76-7	13495-13508	task-specific	_
76-8	13509-13516	changes	_
76-9	13517-13519	in	_
76-10	13520-13523	the	_
76-11	13524-13536	relationship	_
76-12	13537-13544	between	_
76-13	13545-13553	activity	_
76-14	13554-13556	in	_
76-15	13557-13566	different	_
76-16	13567-13572	brain	_
76-17	13573-13578	areas	_
76-18	13579-13580	.	_

77-1	13581-13590	Following	_
77-2	13591-13602	acquisition	_
77-3	13603-13604	,	_
77-4	13605-13618	preprocessing	_
77-5	13619-13621	of	_
77-6	13622-13625	the	_
77-7	13626-13633	imaging	_
77-8	13634-13638	data	_
77-9	13639-13643	will	_
77-10	13644-13651	correct	_
77-11	13652-13655	for	_
77-12	13656-13665	geometric	_
77-13	13666-13676	distortion	_
77-14	13677-13678	,	_
77-15	13679-13683	head	_
77-16	13684-13690	motion	_
77-17	13691-13693	or	_
77-18	13694-13699	other	_
77-19	13700-13709	artifacts	_
77-20	13710-13711	.	_

78-1	13712-13713	A	_
78-2	13714-13718	mask	_
78-3	13719-13721	of	_
78-4	13722-13725	the	_
78-5	13726-13729	two	_
78-6	13730-13734	seed	_
78-7	13735-13742	regions	_
78-8	13743-13747	will	_
78-9	13748-13750	be	_
78-10	13751-13755	made	_
78-11	13756-13761	using	_
78-12	13762-13763	a	_
78-13	13764-13769	12-mm	_
78-14	13770-13778	diameter	_
78-15	13779-13785	sphere	_
78-16	13786-13793	located	_
78-17	13794-13796	in	_
78-18	13797-13800	the	_
78-19	13801-13807	center	_
78-20	13808-13810	of	_
78-21	13811-13814	the	_
78-22	13815-13819	left	_
78-23	13820-13823	and	_
78-24	13824-13829	right	_
78-25	13830-13838	amygdala	_
78-26	13839-13844	using	_
78-27	13845-13848	the	_
78-28	13849-13857	Montreal	_
78-29	13858-13870	Neurological	_
78-30	13871-13880	Institute	_
78-31	13881-13892	coordinates	_
78-32	13893-13894	(	_
78-33	13895-13896	x	_
78-34	13897-13898	,	_
78-35	13899-13900	y	_
78-36	13901-13902	,	_
78-37	13903-13904	z	_
78-38	13905-13906	=	_
78-39	13907-13908	±	_
78-40	13909-13911	22	_
78-41	13912-13913	,	_
78-42	13914-13915	0	_
78-43	13916-13917	,	_
78-44	13918-13921	−22	_
78-45	13922-13923	)	_
78-46	13924-13925	.	_

79-1	13926-13929	For	_
79-2	13930-13934	each	_
79-3	13935-13946	participant	_
79-4	13947-13948	,	_
79-5	13949-13952	the	_
79-6	13953-13957	mean	_
79-7	13958-13967	corrected	_
79-8	13968-13971	and	_
79-9	13972-13976	high	_
79-10	13977-13981	pass	_
79-11	13982-13990	temporal	_
79-12	13991-13999	filtered	_
79-13	14000-14004	time	_
79-14	14005-14011	series	_
79-15	14012-14014	of	_
79-16	14015-14018	the	_
79-17	14019-14037	blood-oxygen-level	_
79-18	14038-14047	dependent	_
79-19	14048-14049	(	_
79-20	14050-14054	BOLD	_
79-21	14055-14056	)	_
79-22	14057-14063	signal	_
79-23	14064-14066	in	_
79-24	14067-14070	the	_
79-25	14071-14079	amygdala	_
79-26	14080-14084	will	_
79-27	14085-14087	be	_
79-28	14088-14097	extracted	_
79-29	14098-14103	using	_
79-30	14104-14105	‘	_
79-31	14106-14115	fslmeants	_
79-32	14116-14117	’	_
79-33	14118-14121	and	_
79-34	14122-14126	used	_
79-35	14127-14129	in	_
79-36	14130-14131	a	_
79-37	14132-14138	single	_
79-38	14139-14146	subject	_
79-39	14147-14152	whole	_
79-40	14153-14158	brain	_
79-41	14159-14162	PPI	_
79-42	14163-14171	analysis	_
79-43	14172-14173	.	_

80-1	14174-14185	Statistical	_
80-2	14186-14194	analysis	_
80-3	14195-14199	will	_
80-4	14200-14202	be	_
80-5	14203-14212	performed	_
80-6	14213-14215	at	_
80-7	14216-14219	the	_
80-8	14220-14238	individual-subject	_
80-9	14239-14244	level	_
80-10	14245-14250	using	_
80-11	14251-14255	FEAT	_
80-12	14256-14257	(	_
80-13	14258-14262	FMRI	_
80-14	14263-14269	Expert	_
80-15	14270-14278	Analysis	_
80-16	14279-14283	Tool	_
80-17	14284-14285	)	_
80-18	14286-14287	.	_

81-1	14288-14291	The	_
81-2	14292-14304	interactions	_
81-3	14305-14307	of	_
81-4	14308-14316	interest	_
81-5	14317-14320	are	_
81-6	14321-14324	the	_
81-7	14325-14331	trauma	_
81-8	14332-14333	(	_
81-9	14334-14336	v.	_
81-10	14337-14344	neutral	_
81-11	14345-14346	)	_
81-12	14347-14348	×	_
81-13	14349-14350	(	_
81-14	14351-14355	left	_
81-15	14356-14358	or	_
81-16	14359-14364	right	_
81-17	14365-14366	)	_
81-18	14367-14375	amygdala	_
81-19	14376-14380	time	_
81-20	14381-14387	series	_
81-21	14388-14391	and	_
81-22	14392-14395	the	_
81-23	14396-14403	alcohol	_
81-24	14404-14405	(	_
81-25	14406-14408	v.	_
81-26	14409-14416	neutral	_
81-27	14417-14418	)	_
81-28	14419-14420	×	_
81-29	14421-14422	(	_
81-30	14423-14427	left	_
81-31	14428-14430	or	_
81-32	14431-14436	right	_
81-33	14437-14438	)	_
81-34	14439-14447	amygdala	_
81-35	14448-14449	.	_

82-1	14450-14451	A	_
82-2	14452-14463	group-level	_
82-3	14464-14472	analysis	_
82-4	14473-14477	will	_
82-5	14478-14481	use	_
82-6	14482-14483	a	_
82-7	14484-14489	mixed	_
82-8	14490-14497	effects	_
82-9	14498-14506	approach	_
82-10	14507-14508	,	_
82-11	14509-14513	with	_
82-12	14514-14522	separate	_
82-13	14523-14528	group	_
82-14	14529-14537	analyses	_
82-15	14538-14541	for	_
82-16	14542-14546	left	_
82-17	14547-14550	and	_
82-18	14551-14556	right	_
82-19	14557-14565	amygdala	_
82-20	14566-14567	.	_

83-1	14568-14571	For	_
83-2	14572-14579	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
83-3	14580-14585	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
83-4	14586-14590	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
83-5	14591-14599	analysis	_
83-6	14600-14601	,	_
83-7	14602-14603	a	_
83-8	14604-14614	seed-based	_
83-9	14615-14623	approach	_
83-10	14624-14628	will	_
83-11	14629-14633	also	_
83-12	14634-14636	be	_
83-13	14637-14641	used	_
83-14	14642-14646	with	_
83-15	14647-14650	the	_
83-16	14651-14655	same	_
83-17	14656-14664	amygdala	_
83-18	14665-14669	seed	_
83-19	14670-14677	regions	_
83-20	14678-14682	used	_
83-21	14683-14685	in	_
83-22	14686-14689	the	_
83-23	14690-14693	PPI	_
83-24	14694-14702	analysis	_
83-25	14703-14704	.	_

84-1	14705-14710	Group	_
84-2	14711-14716	level	_
84-3	14717-14725	analyses	_
84-4	14726-14729	and	_
84-5	14730-14740	extraction	_
84-6	14741-14743	of	_
84-7	14744-14753	parameter	_
84-8	14754-14763	estimates	_
84-9	14764-14768	from	_
84-10	14769-14779	prefrontal	_
84-11	14780-14786	cortex	_
84-12	14787-14788	(	_
84-13	14789-14792	PFC	_
84-14	14793-14794	)	_
84-15	14795-14802	regions	_
84-16	14803-14807	will	_
84-17	14808-14810	be	_
84-18	14811-14814	the	_
84-19	14815-14819	same	_
84-20	14820-14822	as	_
84-21	14823-14826	for	_
84-22	14827-14830	the	_
84-23	14831-14834	PPI	_
84-24	14835-14843	analysis	_
84-25	14844-14845	.	_

85-1	14846-14848	To	_
85-2	14849-14853	test	_
85-3	14854-14864	hypotheses	_
85-4	14865-14867	3A	_
85-5	14868-14871	and	_
85-6	14872-14874	3B	_
85-7	14875-14879	that	_
85-8	14880-14892	connectivity	_
85-9	14893-14900	between	_
85-10	14901-14904	the	_
85-11	14905-14908	PFC	_
85-12	14909-14912	and	_
85-13	14913-14916	the	_
85-14	14917-14921	left	_
85-15	14922-14924	or	_
85-16	14925-14930	right	_
85-17	14931-14939	amygdala	_
85-18	14940-14942	in	_
85-19	14943-14951	response	_
85-20	14952-14954	to	_
85-21	14955-14959	cues	_
85-22	14960-14962	at	_
85-23	14963-14971	baseline	_
85-24	14972-14976	will	_
85-25	14977-14984	predict	_
85-26	14985-14991	change	_
85-27	14992-14994	in	_
85-28	14995-14999	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
85-29	15000-15003	and	_
85-30	15004-15007	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
85-31	15008-15016	severity	_
85-32	15017-15020	due	_
85-33	15021-15023	to	_
85-34	15024-15033	treatment	_
85-35	15034-15035	,	_
85-36	15036-15044	separate	_
85-37	15045-15051	linear	_
85-38	15052-15062	regression	_
85-39	15063-15068	tests	_
85-40	15069-15073	will	_
85-41	15074-15076	be	_
85-42	15077-15081	used	_
85-43	15082-15083	.	_

86-1	15084-15091	Changes	_
86-2	15092-15094	in	_
86-3	15095-15099	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
86-4	15100-15103	and	_
86-5	15104-15107	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
86-6	15108-15116	severity	_
86-7	15117-15121	will	_
86-8	15122-15124	be	_
86-9	15125-15134	regressed	_
86-10	15135-15142	against	_
86-11	15143-15146	the	_
86-12	15147-15156	parameter	_
86-13	15157-15165	estimate	_
86-14	15166-15174	obtained	_
86-15	15175-15179	from	_
86-16	15180-15183	the	_
86-17	15184-15189	voxel	_
86-18	15190-15194	with	_
86-19	15195-15198	the	_
86-20	15199-15206	maximum	_
86-21	15207-15214	Z-score	_
86-22	15215-15219	from	_
86-23	15220-15224	each	_
86-24	15225-15228	PFC	_
86-25	15229-15236	cluster	_
86-26	15237-15241	that	_
86-27	15242-15251	exhibited	_
86-28	15252-15253	a	_
86-29	15254-15265	significant	_
86-30	15266-15277	association	_
86-31	15278-15282	with	_
86-32	15283-15286	the	_
86-33	15287-15295	amygdala	_
86-34	15296-15300	time	_
86-35	15301-15307	series	_
86-36	15308-15310	at	_
86-37	15311-15315	rest	_
86-38	15316-15317	,	_
86-39	15318-15321	and	_
86-40	15322-15323	a	_
86-41	15324-15335	significant	_
86-42	15336-15340	task	_
86-43	15341-15342	×	_
86-44	15343-15347	seed	_
86-45	15348-15359	interaction	_
86-46	15360-15364	with	_
86-47	15365-15368	the	_
86-48	15369-15377	amygdala	_
86-49	15378-15380	in	_
86-50	15381-15389	response	_
86-51	15390-15392	to	_
86-52	15393-15396	the	_
86-53	15397-15403	trauma	_
86-54	15404-15407	cue	_
86-55	15408-15409	(	_
86-56	15410-15420	Hypothesis	_
86-57	15421-15423	3A	_
86-58	15424-15425	)	_
86-59	15426-15429	and	_
86-60	15430-15437	alcohol	_
86-61	15438-15441	cue	_
86-62	15442-15443	(	_
86-63	15444-15454	Hypothesis	_
86-64	15455-15457	3B	_
86-65	15458-15459	)	_
86-66	15460-15461	.	_

